JP2017522025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522025A5 JP2017522025A5 JP2017502212A JP2017502212A JP2017522025A5 JP 2017522025 A5 JP2017522025 A5 JP 2017522025A5 JP 2017502212 A JP2017502212 A JP 2017502212A JP 2017502212 A JP2017502212 A JP 2017502212A JP 2017522025 A5 JP2017522025 A5 JP 2017522025A5
- Authority
- JP
- Japan
- Prior art keywords
- oncolytic virus
- virus
- activity
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306153.9 | 2014-07-16 | ||
| EP14306153 | 2014-07-16 | ||
| PCT/EP2015/066263 WO2016008976A1 (en) | 2014-07-16 | 2015-07-16 | Oncolytic virus for expression of immune checkpoint modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163305A Division JP7077377B2 (ja) | 2014-07-16 | 2020-09-29 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522025A JP2017522025A (ja) | 2017-08-10 |
| JP2017522025A5 true JP2017522025A5 (enExample) | 2018-08-16 |
| JP6895374B2 JP6895374B2 (ja) | 2021-06-30 |
Family
ID=51220528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502212A Active JP6895374B2 (ja) | 2014-07-16 | 2015-07-16 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| JP2020163305A Active JP7077377B2 (ja) | 2014-07-16 | 2020-09-29 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163305A Active JP7077377B2 (ja) | 2014-07-16 | 2020-09-29 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10555981B2 (enExample) |
| EP (2) | EP3552615B8 (enExample) |
| JP (2) | JP6895374B2 (enExample) |
| CN (2) | CN107208069A (enExample) |
| AU (2) | AU2015289125B2 (enExample) |
| CA (2) | CA2954841A1 (enExample) |
| DK (2) | DK3552615T3 (enExample) |
| ES (2) | ES2909957T3 (enExample) |
| HU (1) | HUE045108T2 (enExample) |
| IL (1) | IL250058A0 (enExample) |
| PL (1) | PL3169341T3 (enExample) |
| PT (1) | PT3169341T (enExample) |
| RU (1) | RU2696312C2 (enExample) |
| WO (1) | WO2016008976A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3381942T4 (fi) * | 2012-08-30 | 2025-12-16 | Amgen Inc | Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| US10765710B2 (en) * | 2014-07-16 | 2020-09-08 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| EP3552615B8 (en) * | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| WO2016065330A1 (en) | 2014-10-24 | 2016-04-28 | Aladar Szalay | Combination immunotherapy approach for treatment of cancer |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| RS61943B1 (sr) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Imunomodulatorni proteini sa prilagodljivim afinitetima |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| JP2018527895A (ja) | 2015-06-29 | 2018-09-27 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法 |
| US20200046671A1 (en) * | 2015-06-29 | 2020-02-13 | Regents Of The University Of Minnesota | Apobec3b mutagenesis and immunotherapy |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| EA201800148A1 (ru) | 2015-08-11 | 2019-01-31 | Калиди Биотерапьютикс, Инк. | Оспенная вакцина для лечения рака |
| ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| HUE060517T2 (hu) | 2015-12-22 | 2023-03-28 | X4 Pharmaceuticals Inc | Immunhiányos betegség kezelésére szolgáló eljárások |
| WO2017118866A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Engineered virus |
| EP3405203A4 (en) * | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| ES2919953T3 (es) | 2016-01-27 | 2022-07-29 | Oncorus Inc | Vectores víricos oncolíticos y usos de los mismos |
| US10512662B2 (en) | 2016-02-25 | 2019-12-24 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| US10736962B2 (en) | 2016-02-25 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| US11414491B2 (en) | 2016-05-18 | 2022-08-16 | Mayo Foundation For Medical Education And Research | Targeting PD-L1 on tumor cells |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| WO2017223229A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109983121A (zh) * | 2016-06-30 | 2019-07-05 | 昂克诺斯公司 | 治疗性多肽的假型化溶瘤病毒递送 |
| US20190367886A1 (en) * | 2016-07-13 | 2019-12-05 | National University Corporation Tottori Tottori University | Method for producing vaccinia virus expressing foreign gene |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018024849A1 (en) * | 2016-08-03 | 2018-02-08 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| TW201825674A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN110381997A (zh) * | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| MX2019008922A (es) * | 2017-01-30 | 2020-01-20 | Epicentrx Inc | Mutantes de la caja tata y de la caja caat selectivas de tumor. |
| AU2018228308B2 (en) * | 2017-02-28 | 2022-01-27 | Genemedicine Co., Ltd. | Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3630807B1 (en) | 2017-05-25 | 2025-08-13 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| RU2771110C2 (ru) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2019074983A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| WO2019084418A1 (en) * | 2017-10-27 | 2019-05-02 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER |
| EP3710018A4 (en) * | 2017-11-16 | 2022-03-09 | Virogin Biotech Canada Ltd | ONCOLYTIC VIRUSES DECORATED BY A TARGETING FRACTION |
| CN108165536A (zh) * | 2017-12-11 | 2018-06-15 | 浙江大学 | 一种重组溶瘤痘苗病毒及其制备方法与应用 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| MX2020007010A (es) | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
| CA3088609C (en) * | 2018-01-19 | 2024-02-13 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
| US11786569B2 (en) * | 2018-01-26 | 2023-10-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| WO2019151836A1 (en) * | 2018-02-05 | 2019-08-08 | Sillajen, Inc. | Oncolytic vaccinia virus expressing an immune checkpoint protein antagonist to treat cancer |
| WO2019168346A1 (ko) * | 2018-02-28 | 2019-09-06 | 주식회사 바이오녹스 | 항암바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| CN108329378B (zh) * | 2018-03-12 | 2020-09-25 | 华中农业大学 | 塞内卡谷病毒vp1蛋白、编码基因、杂交瘤细胞株和单克隆抗体及其应用 |
| KR20200131863A (ko) * | 2018-03-13 | 2020-11-24 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스 |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| US20210196771A1 (en) * | 2018-08-16 | 2021-07-01 | Systems Oncology, Llc | Recombinant myxoma viruses and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| EP3856216A4 (en) * | 2018-09-10 | 2022-10-05 | Genesail Biotech (Shanghai) Co. Ltd. | MODIFIED ONCOLYTIC VIRUS, COMPOSITION AND USE THEREOF |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| CN111100846A (zh) | 2018-10-26 | 2020-05-05 | 上海元宋生物技术有限公司 | 表达pd-1结合蛋白的溶瘤病毒及其应用 |
| CA3116412A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| JP7646542B2 (ja) * | 2018-11-01 | 2025-03-17 | バイオインベント インターナショナル アクティエボラーグ | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
| CN113271955A (zh) | 2018-11-06 | 2021-08-17 | 卡利迪生物治疗有限公司 | 用于细胞介导的溶瘤病毒疗法的增强的系统 |
| EP3906038A4 (en) | 2018-11-21 | 2022-06-01 | Mayo Foundation for Medical Education and Research | ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS |
| CN109627336A (zh) * | 2018-12-20 | 2019-04-16 | 南京昂科利医药科技创新研究院有限公司 | 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用 |
| JP2022516006A (ja) * | 2018-12-21 | 2022-02-24 | オタワ ホスピタル リサーチ インスティチュート | 修飾オルソポックスウイルスベクター |
| CN113453712A (zh) | 2018-12-28 | 2021-09-28 | 特兰斯吉恩股份有限公司 | M2缺陷型痘病毒 |
| EP3917552A1 (en) * | 2019-01-29 | 2021-12-08 | Arno Thaller | Recombinant oncolytic newcastle disease viruses with increased activity |
| CN109913425B (zh) * | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| AU2020266125B2 (en) | 2019-04-29 | 2023-04-13 | Mayo Foundation For Medical Education And Research | Multivalent PD-L1 binding compounds for treating cancer |
| JP7606471B2 (ja) | 2019-05-22 | 2024-12-25 | レイドス， インコーポレイテッド | Ｌａｇ３結合ペプチド |
| AU2020315800A1 (en) | 2019-07-19 | 2022-03-03 | Seneca Therapeutics, Inc. | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| CN120037270A (zh) * | 2019-08-26 | 2025-05-27 | 拜耳诺克斯有限公司 | 包含痘苗病毒和羟基脲作为活性成分的用于治疗癌症的药物组合物 |
| CA3163805A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| WO2021168186A1 (en) * | 2020-02-20 | 2021-08-26 | Eric Bartee | Recombinant myxoma viruses and uses thereof |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
| WO2021226551A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| US20230277633A1 (en) * | 2020-06-05 | 2023-09-07 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical composition of enzymes and viruses and application thereof |
| US11578102B2 (en) | 2020-07-31 | 2023-02-14 | Leidos, Inc. | LAG3 binding peptides |
| JP2023548662A (ja) | 2020-10-12 | 2023-11-20 | レイドス， インコーポレイテッド | 免疫調節性ペプチド |
| US20230381309A1 (en) * | 2020-10-13 | 2023-11-30 | Immunovaccine Technologies Inc. | Methods of treating diffuse large b-cell lymphoma |
| EP4249596A4 (en) * | 2020-11-17 | 2025-03-12 | National University Corporation Tottori University | NEW GENE RECOMBINANT VACCINIAVIRUS AND USE THEREOF |
| CN112641798A (zh) * | 2020-12-29 | 2021-04-13 | 武汉博威德生物技术有限公司 | 一种提高重组柯萨奇病毒溶瘤作用的方法 |
| CA3207860A1 (en) * | 2021-01-11 | 2022-07-14 | Seneca Therapeutics, Inc. | Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| CA3206004A1 (en) * | 2021-02-02 | 2022-08-11 | Mary Jo Hauser | Viral constructs for use in enhancing t-cell priming during vaccination |
| WO2022182206A1 (ko) * | 2021-02-26 | 2022-09-01 | 신라젠(주) | 항암 바이러스 및 이의 용도 |
| CN114934065A (zh) * | 2021-11-25 | 2022-08-23 | 浙江理工大学绍兴生物医药研究院有限公司 | 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用 |
| CN120648657A (zh) * | 2024-03-08 | 2025-09-16 | 上海锦斯生物技术有限公司 | 一种修饰的溶瘤病毒及其组合物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| CA2799545A1 (en) | 2000-03-07 | 2001-09-13 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| GB0128288D0 (en) | 2001-11-27 | 2002-01-16 | Siddall & Hilton Ltd | Spring location means |
| ATE300954T1 (de) | 2001-12-10 | 2005-08-15 | Bavarian Nordic As | Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| NZ536746A (en) | 2002-06-13 | 2007-02-23 | Crucell Holland Bv | An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| CN1826410B (zh) | 2003-07-21 | 2011-10-26 | 特兰斯吉恩股份有限公司 | 具有改良的胞嘧啶脱氨酶活性的多肽 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP2292246A1 (en) | 2004-11-12 | 2011-03-09 | Bayer Schering Pharma Aktiengesellschaft | Recombinant Newcastle Disease Virus |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101510065B1 (ko) | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| JP5138601B2 (ja) | 2005-11-21 | 2013-02-06 | サノフィ パストゥール リミテッド | 組換えウイルス安定化製剤 |
| US9868961B2 (en) | 2006-03-30 | 2018-01-16 | The Regents Of The University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
| ES2611975T3 (es) | 2006-06-20 | 2017-05-11 | Transgene S.A. | Procedimiento para producir poxvirus y composiciones de poxvirus |
| BRPI0713711A2 (pt) | 2006-06-20 | 2012-10-30 | Transgene Sa | vacina viral recombinante, kit para vacinação, e, método para usar pelo menos um composto |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| US8012738B2 (en) | 2007-05-14 | 2011-09-06 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| NZ584201A (en) | 2007-11-19 | 2012-06-29 | Transgene Sa | Poxviral oncolytic vectors comprising a defective f2l gene |
| US9687515B2 (en) * | 2007-11-19 | 2017-06-27 | Transgene S.A. | Poxviral oncolytic vectors |
| BRPI0820576B1 (pt) * | 2007-11-19 | 2021-10-19 | Transgène S.A. | Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo |
| KR20210049186A (ko) | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| EP2240573A4 (en) | 2008-02-12 | 2011-08-31 | Sanofi Pasteur Ltd | METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| NZ596595A (en) | 2009-05-12 | 2013-05-31 | Transgene Sa | Method for orthopoxvirus production and purification |
| MX342017B (es) | 2010-03-26 | 2016-09-09 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| ES2813413T3 (es) | 2011-08-05 | 2021-03-23 | Sillajen Biotherapeutics Inc | Métodos y composiciones para la producción de virus vaccina |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| KR20170039774A (ko) | 2012-07-30 | 2017-04-11 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| EP3552615B8 (en) * | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| CN108165536A (zh) * | 2017-12-11 | 2018-06-15 | 浙江大学 | 一种重组溶瘤痘苗病毒及其制备方法与应用 |
| KR20200131863A (ko) * | 2018-03-13 | 2020-11-24 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스 |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
-
2015
- 2015-07-16 EP EP19174121.4A patent/EP3552615B8/en active Active
- 2015-07-16 PL PL15738359T patent/PL3169341T3/pl unknown
- 2015-07-16 CA CA2954841A patent/CA2954841A1/en active Pending
- 2015-07-16 DK DK19174121.4T patent/DK3552615T3/da active
- 2015-07-16 HU HUE15738359A patent/HUE045108T2/hu unknown
- 2015-07-16 JP JP2017502212A patent/JP6895374B2/ja active Active
- 2015-07-16 RU RU2017103162A patent/RU2696312C2/ru active
- 2015-07-16 CN CN201580050076.8A patent/CN107208069A/zh active Pending
- 2015-07-16 PT PT15738359T patent/PT3169341T/pt unknown
- 2015-07-16 AU AU2015289125A patent/AU2015289125B2/en active Active
- 2015-07-16 DK DK15738359.7T patent/DK3169341T3/da active
- 2015-07-16 CN CN202510690099.0A patent/CN120555373A/zh active Pending
- 2015-07-16 ES ES19174121T patent/ES2909957T3/es active Active
- 2015-07-16 EP EP15738359.7A patent/EP3169341B1/en active Active
- 2015-07-16 WO PCT/EP2015/066263 patent/WO2016008976A1/en not_active Ceased
- 2015-07-16 US US15/325,562 patent/US10555981B2/en active Active
- 2015-07-16 ES ES15738359T patent/ES2743873T3/es active Active
- 2015-07-16 CA CA3190510A patent/CA3190510A1/en active Pending
-
2017
- 2017-01-11 IL IL250058A patent/IL250058A0/en active IP Right Grant
-
2019
- 2019-12-23 US US16/725,485 patent/US11779619B2/en active Active
-
2020
- 2020-01-24 AU AU2020200541A patent/AU2020200541B2/en active Active
- 2020-09-29 JP JP2020163305A patent/JP7077377B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017103162A (ru) | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек | |
| EP4232463B1 (en) | Interleukin-2-fc fusion proteins and methods of use | |
| RU2017103151A (ru) | Комбинация онколитического вируса с модуляторами иммунологических контрольных точек | |
| Pol et al. | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors | |
| Pol et al. | Trial Watch—Oncolytic viruses and cancer therapy | |
| JP2021527694A5 (enExample) | ||
| JP2019508017A (ja) | 抗ｔｃｒ複合体抗体又は断片をコードするウイルス | |
| JP2019500909A5 (enExample) | ||
| US11142580B2 (en) | Oncolytic virus and method | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| JP2022536929A5 (enExample) | ||
| CN116529258A (zh) | 白介素-2-Fc融合蛋白和使用方法 | |
| US20250297002A1 (en) | Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereof | |
| Zhang et al. | Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy | |
| JP2023552289A5 (enExample) | ||
| JP2021522190A5 (enExample) | ||
| JP2024517641A (ja) | 免疫細胞の遺伝子改変および治療的使用のための方法および組成物 | |
| EP4023232B1 (en) | Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients | |
| EP3868876A1 (en) | New oncolytic newcastle disease viruses and recombinant ndv strains | |
| HK40096948A (zh) | 白介素-2-fc融合蛋白和使用方法 | |
| HK40097253A (en) | Interleukin-2-fc fusion proteins and methods of use | |
| EP4703386A1 (en) | Antibody specifically binding to cd276, preparation method therefor and use thereof | |
| Zupko | Oncolytic viruses in cancer immunotherapy | |
| HK40012869A (en) | Oncolytic viruses and therapeutic molecules |